Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;94(12):4851-9.
doi: 10.1210/jc.2009-1500. Epub 2009 Oct 22.

Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome

Affiliations

Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome

Elena Valassi et al. J Clin Endocrinol Metab. 2009 Dec.

Abstract

Context: The ability of combined dexamethasone-corticotropin releasing hormone (Dex-CRH) testing to distinguish pseudo-Cushing's syndrome (PCS) from Cushing's syndrome is controversial. One factor potentially impairing diagnostic efficacy is the concomitant use of commonly prescribed medications that may alter dexamethasone metabolism.

Objective: Our objective was to assess the diagnostic accuracy of the Dex-CRH test and evaluate the potential impact of concomitant drugs.

Design: The study was a retrospective one.

Participants: Participants included 101 patients [60 Cushing's disease (CD); 41 PCS] who underwent 112 Dex-CRH tests. Patients were divided into two groups, depending on use of medications potentially interfering with dexamethasone metabolism: 58 tests were classified as No Meds (32 CD; 26 PCS) and 54 as Meds (34 CD; 20 PCS). The latter group was further subdivided into patients taking one medication vs. those taking multiple medications.

Main outcome measures: Diagnostic accuracy of different serum cortisol and ACTH thresholds at baseline and 15 min after CRH injection was assessed.

Results: The specificity of a baseline post-low-dose-dexamethasone-suppressed test cortisol lower than 1.4 microg/dl (38 nmol/liter) was significantly higher in the No Meds vs. the Meds group (P = 0.014). Sensitivity and specificity using a post-CRH cortisol cutoff of 1.4 microg/dl (38 nmol/liter) were 93.1% (95% confidence interval = 88.4-97.8) and 92.3% (95% confidence interval = 87-97.6) in the No Meds group. The specificity of a cortisol lower than 1.4 microg/dl (38 nmol/l) at 15 min after CRH was significantly higher in patients taking only one medication vs. those on multidrug treatment (P < 0.05).

Conclusions: Medications commonly prescribed in hypercortisolemic patients undergoing Dex-CRH testing may contribute to the variable diagnostic accuracy of this test. Prospective studies to address this issue are needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A, Individual cortisol responses in patients with CD (•) and PCS (○) at baseline post-LDDST (cortisol 0) and 15 minutes post-CRH (cortisol 15). Cutoff A = 1.4 μg/dl (38 nmol/L); cutoff B = 1.8 μg/dl (50 nmol/L); cutoff C = 4 μg/dl (110 nmol/L). B, Individual ACTH responses in patients with CD (•) and PCS (○) at baseline post-LDDST (ACTH 0) and 15 minutes post-CRH (ACTH 15). Cutoff A = 6 pg/ml (1.3 pmol/L); cutoff B = 16 pg/ml (3.5 pmol/L); cutoff C = 27 pg/ml (5.9 pmol/L).

Similar articles

Cited by

References

    1. Findling JW, Raff H 2006 Cushing’s syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91:3746–3753 - PubMed
    1. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM 2008 The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526–1540 - PMC - PubMed
    1. Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, Gin H, Roger P, Tabarin A 2003 Occult Cushing’s syndrome in type 2 diabetes. J Clin Endocrinol Metab 88:5808–5813 - PubMed
    1. Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, Santini SA, Guglielmi G, Carnevale V, Scillitani A 2007 Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 147: 541–548 - PubMed
    1. Yanovski JA, Cutler Jr GB, Chrousos GP, Nieman LK 1993 Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. JAMA 269: 2232–2238 - PubMed

Publication types